ArticleHaematologica2012

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.

Harald Herrmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.